Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients.

Harel NY, Cudkowicz ME, Brown RH, Strittmatter SM.

Biomarkers. 2009 Sep;14(6):414-7. doi: 10.1080/13547500903056051.

2.

Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis.

Dupuis L, Gonzalez de Aguilar JL, di Scala F, Rene F, de Tapia M, Pradat PF, Lacomblez L, Seihlan D, Prinjha R, Walsh FS, Meininger V, Loeffler JP.

Neurobiol Dis. 2002 Aug;10(3):358-65.

PMID:
12270696
3.

[Significance of Nogo-A expression of atrophic muscle fibers in diagnosis of amyotrophic lateral sclerosis].

Sun AP, Zhang J, Liao Q, Tang L, Fan DS.

Beijing Da Xue Xue Bao. 2011 Apr 18;43(2):238-41. Chinese.

4.

Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity.

Jokic N, Gonzalez de Aguilar JL, Pradat PF, Dupuis L, Echaniz-Laguna A, Muller A, Dubourg O, Seilhean D, Hauw JJ, Loeffler JP, Meininger V.

Ann Neurol. 2005 Apr;57(4):553-6.

PMID:
15786457
5.

Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease.

Wojcik S, Engel WK, Askanas V.

Acta Myol. 2006 Dec;25(3):116-8.

PMID:
17626519
6.

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A.

Neurology. 2015 Jun 2;84(22):2247-57. doi: 10.1212/WNL.0000000000001642. Erratum in: Neurology. 2015 Sep 8;85(10):921.

7.

Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Ren Y, Zhu W, Cui F, Yang F, Chen Z, Ling L, Huang X.

Int J Clin Exp Pathol. 2015 May 1;8(5):5419-26.

8.

Decreased level of serum autoantibody against LG72 is a biosignature of amyotrophic lateral sclerosis.

Hwang CS, Tsai CH, Liu GT, Li W, Chang HT.

Biomark Med. 2016;10(1):73-9. doi: 10.2217/bmm.15.80.

PMID:
26673967
9.

Elevated serum angiogenin levels in ALS.

Cronin S, Greenway MJ, Ennis S, Kieran D, Green A, Prehn JH, Hardiman O.

Neurology. 2006 Nov 28;67(10):1833-6.

PMID:
17130418
10.

Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, Lacomis D, Cudkowicz M, Bowser R.

Muscle Nerve. 2010 Jul;42(1):104-11. doi: 10.1002/mus.21683.

11.

Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.

Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker D, Amor S, Malaspina A.

J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):274-8. doi: 10.1136/jnnp-2013-305494.

PMID:
24078718
12.

Muscle Nogo-A: a marker for amyotrophic lateral sclerosis or for denervation?

T├ągerud S, Libelius R, Magnusson C.

Ann Neurol. 2007 Dec;62(6):676. No abstract available.

PMID:
17702029
13.

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.

Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick JP, Monsch AU, Regeniter A, Lindberg RL, Kappos L, Leppert D, Petzold A, Giovannoni G, Kuhle J.

PLoS One. 2013 Sep 20;8(9):e75091. doi: 10.1371/journal.pone.0075091.

14.

Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Kasai T, Tokuda T, Ishigami N, Sasayama H, Foulds P, Mitchell DJ, Mann DM, Allsop D, Nakagawa M.

Acta Neuropathol. 2009 Jan;117(1):55-62. doi: 10.1007/s00401-008-0456-1.

PMID:
18989684
15.

Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis.

Askanas V, Wojcik S, Engel WK.

Ann Neurol. 2007 Dec;62(6):676-7; author reply 677. No abstract available.

PMID:
17894379
16.

Humoral factors in ALS patients during disease progression.

Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, Kim SH, Sanberg CD, Vu TH, Gooch CL, Sanberg PR, Garbuzova-Davis S.

J Neuroinflammation. 2015 Jun 28;12:127. doi: 10.1186/s12974-015-0350-4.

17.

Alterations in muscle proteome of patients diagnosed with amyotrophic lateral sclerosis.

Elf K, Shevchenko G, Nygren I, Larsson L, Bergquist J, Askmark H, Artemenko K.

J Proteomics. 2014 Aug 28;108:55-64. doi: 10.1016/j.jprot.2014.05.004.

PMID:
24846852
18.

Transglutaminase 6 Antibodies in the Serum of Patients With Amyotrophic Lateral Sclerosis.

Gadoth A, Nefussy B, Bleiberg M, Klein T, Artman I, Drory VE.

JAMA Neurol. 2015 Jun;72(6):676-81. doi: 10.1001/jamaneurol.2015.48.

PMID:
25867286
19.

Decreased urinary concentrations of type IV collagen in amyotrophic lateral sclerosis.

Ono S, Imai T, Matsubara S, Takahashi K, Jinnai K, Yamano T, Shimizu N.

Acta Neurol Scand. 1999 Aug;100(2):111-6.

PMID:
10442453
20.

Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations.

Bowser R, Turner MR, Shefner J.

Nat Rev Neurol. 2011 Oct 11;7(11):631-8. doi: 10.1038/nrneurol.2011.151. Review.

PMID:
21989244
Items per page

Supplemental Content

Support Center